Bayer to buy Teva’s U.S. animal health business
Posted on October 17, 2012
Bayer HealthCare LLC and Teva Pharmaceutical Industries Ltd. announced Sept. 14 that they have signed an agreement for Bayer to acquire the U.S.-based animal health business of Teva for up to $145 million.
The acquisition will allow Bayer to expand its U.S. product lines for companion and food animals and will allow Teva to focus on human health. The transaction encompasses a manufacturing site in St. Joseph, Mo., and about 300 employees.
Teva’s portfolio in companion animal health includes dermatologic, wellness, and nutraceutical products. Teva’s products for food animals include anti-infectives, parasiticides, anti-inflammatories, and reproductive hormones.